Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the ...

Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...

In an episode of "The David Rubenstein Show: Peer to Peer Conversations," CEO Dave Ricks talks about how the company will begin studies this year to see if its weight-loss medicines can also be ...

Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 463.56% and ...

Artemi Panarin scored two goals, Chris Kreider had the go-ahead goal off a defensive deflection with 9:38 to play, and the ...

Prog veteran recalls connecting with Sandy Denny, his band’s attempt to fire him, being loved by Led Zeppelin, why they’ve never had a Steven Wilson remix, the “albatross” of Part Of The Union and the ...

Pills would be more convenient for patients and also easier to manufacture at large scale than other top weight-loss drugs, which require , CEO Dave Ricks said.

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

CEO Dave Ricks told Bloomberg News on Monday that data on the drug, orforglipron, is expected before the middle of 2025. That could lead to regulatory clearance the following year, Ricks said in ...